Generex Receives Canadian Approval For Phase III Oralin Trials

Generex Biotechnology Corp. has received regulatory approval from Canada's Health Protection Branch to conduct late Phase II/Phase III clinical trials of Oralin, an oral insulin formulation. The trials are designed to demonstrate Oralin's bioavailability and efficacy in Type I and Type II (insulin dependent) diabetic patients.

Oralin, Generex's oral insulin formulation

The trials will be conducted under the direction of Dr. Bernard Zinman at the Banting and Best Diabetes Care Center, University of Toronto. Dr. Pankaj Modi, Generex's vice president of Research and Development, will act as coordinator for the studies.

For more information: Generex Biotechnology Corp., 33 Harbour Square, Suite 202, Toronto, Ontario, Canada M5J 2G2. Telephone: 416-364-2551. Fax: 416-364-9363.